Caldieraro M., Walsh S., Deckersbach T., Bobo W., Gao K., Ketter T., Shelton R., Harrington N., Tohen M., Calabrese J., Thase M., Kocsis J., Sylvia L., Nierenberg A.A. Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry (in press).

A Clinician's Guide to Learning Disabilities. Author, Lee Ascherman, M.D. and co-authored with Carleen Franz, PhD. and Julie Shaftel, Ph.D. Oxford Press

Kraguljac NV, Lahti AC (2017). Paving the way towards targeted drug development in schizophrenia. JAMA Psychiatry, in press

Daly E.J., Singh J.B., Fedgchin M., Cooper K., Lim P., Shelton R.C., Thase, M.E., Winokur A., Van Nueten N., Manji H., Drevets, W.C. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: Results of a double-blind, doubly-randomized, placebo-controlled study. JAMA Psychiatry (in press).

Köhler-Forsberg O., Sylvia L., Deckersbach T., Ostacher M.J., McInnis M., Iosifescu D.V., Bowden C.L., McElroy S., Calabrese J.R., Thase M., Shelton R.C., Tohen M., Kocsis J.H., Friedman E.S., Ketter T.A., Nierenberg A.A. Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica (in press).